Browse Studies — Arctuva

Phase 3

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with…

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Chronic LymphocyticSmall-Cell Lymphoma+3 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT05947851

Phase 4

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic …

Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07218341

Long-term Follow-up Study of Patients Receiving CAR-T Cells

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wis…

Chronic Lymphocytic LeukemiaLymphomas Non-Hodgkin's B-CellLymphoma, Small Lymphocytic+6 more

Estimated

~$10 – $750

Medical College of WisconsinNCT03375619